small molecule

ARAZLO

TAZAROTENE

Loss of exclusivityMay 2038latest FDA-listed patent expiry
CompanyBAUSCH HEALTH US LLC

Drug detail

Brand nameARAZLO
Active ingredientTAZAROTENE
Strength0.045%
Dosage formLOTION
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusRX

Listed patents

PatentExpiresType
11311482May 2038use U-2368
12128137May 2038product
11679116June 2036product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ARAZLO patent cliff — loss of exclusivity May 2038 | CliffBio